BEAM sharply up
Beam reported a wider quarterly net loss with no product revenue disclosed, kept its cash runway into mid-2029, highlighted risto-cel BLA and BEAM-302/304/301 clinical milestones, named a new chief commercial officer, and the stock is sharply higher with Wedbush raising its target.
Previous verdicts for BEAM
- AI Search: Beam Therapeutics Slips Modestly Despite Positive Risto-cel Pivotal Data — 2026-11-10
- Analyst PT cut — 2026-11-05
- AI Search: Beam Therapeutics Rises Modestly on Bullish BEAM-301 Clinical Data — 2026-10-28
- AI Search: Beam Therapeutics Rallies Sharply on BEAM-301 Clinical Data — 2026-10-27
- AI Search: BEAM Climbs Modestly on Mixed News and No Clear Catalyst — 2026-10-19
Ezbrisk weighs each event against the market reaction and publishes a verdict with an overreaction reading. How the methodology works